GLP1R and type 2 diabetes mellitus: In addition to the optimization of pharmacotherapy for T2DM treatment, GUT-DOCK can also be used to design novel active pharmaceutical ingredients (API) which demonstrate agonist/antagonist activity when bound to either orthosteric or allosteric binding sites in the transmembrane domains of GCGR, GIPR, GLP1R, VIPR1 and PAC1R receptors.